Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) had its price objective hoisted by equities research analysts at HC Wainwright from $68.00 to $70.00 in a research note issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 32.58% from the company's previous close.
A number of other analysts have also weighed in on HALO. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $61.44.
Check Out Our Latest Analysis on Halozyme Therapeutics
Halozyme Therapeutics Price Performance
HALO stock traded down $0.96 during trading on Friday, hitting $52.80. The company had a trading volume of 2,146,512 shares, compared to its average volume of 1,784,019. The business has a 50 day moving average of $50.23 and a 200 day moving average of $54.00. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of 17.48, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53.
Insiders Place Their Bets
In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.70% of the company's stock.
Hedge Funds Weigh In On Halozyme Therapeutics
Hedge funds have recently made changes to their positions in the business. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics in the second quarter valued at about $49,000. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics in the third quarter valued at about $57,000. FSC Wealth Advisors LLC bought a new stake in Halozyme Therapeutics in the third quarter valued at about $65,000. Finally, Park Place Capital Corp increased its stake in Halozyme Therapeutics by 828.1% in the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock valued at $78,000 after acquiring an additional 1,209 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
